Recap: Monopar Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Monopar Therapeutics (NASDAQ:MNPR) reported its Q3 earnings, beating estimated earnings by 17.65% with an EPS of $-0.14 versus an estimate of $-0.17. However, revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.02, which was followed by a 5.21% drop in the share price the next day.
November 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Monopar Therapeutics reported better than expected Q3 earnings but saw no change in revenue from the same period last year. Last quarter's earnings beat was followed by a drop in share price.
While Monopar Therapeutics beat earnings estimates, the lack of revenue growth and the historical trend of share price dropping after an earnings beat could potentially neutralize any positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100